Cyclin-dependent kinase inhibitors: A survey of the recent patent literature

Paolo Pevarello, Manuela Villa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Since the mid-1990s cyclin-dependent kinase (CDK) inhibition has been the subject of an intense drug discovery effort in the pharmaceutical industry and in some academic institutions. Although only few compounds have at present progressed into human clinical trials, the prospect of finding safe agents useful in therapy, particularly in the cancer setting, is still positive. Some trends can be observed that witness the impact of recent findings in CDK basic biological research and technology advancements on the evolution of the patent literature on CDK inhibition. A patent literature review of small organic molecules as CDK inhibitors comprising the years 2001 - 2004 is presented here, as many of the major pharmaceutical companies have shown a continued effort in the field.

Original languageEnglish
Pages (from-to)675-703
Number of pages29
JournalExpert Opinion on Therapeutic Patents
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Literature
Patents
Cyclin-Dependent Kinases
patent
pharmaceutical industry
pharmaceutical
witness
cancer
drug
Drug Industry
Drug Discovery
trend
Clinical Trials
Technology
Surveys and Questionnaires
literature
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Cancer treatment
  • Cell cycle
  • Cyclin-dependent kinase (CDK)
  • Inhibitor

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law

Cite this

Cyclin-dependent kinase inhibitors : A survey of the recent patent literature. / Pevarello, Paolo; Villa, Manuela.

In: Expert Opinion on Therapeutic Patents, Vol. 15, No. 6, 06.2005, p. 675-703.

Research output: Contribution to journalArticle

Pevarello, Paolo ; Villa, Manuela. / Cyclin-dependent kinase inhibitors : A survey of the recent patent literature. In: Expert Opinion on Therapeutic Patents. 2005 ; Vol. 15, No. 6. pp. 675-703.
@article{27707c8659ba4aeea9a7bc714af8d121,
title = "Cyclin-dependent kinase inhibitors: A survey of the recent patent literature",
abstract = "Since the mid-1990s cyclin-dependent kinase (CDK) inhibition has been the subject of an intense drug discovery effort in the pharmaceutical industry and in some academic institutions. Although only few compounds have at present progressed into human clinical trials, the prospect of finding safe agents useful in therapy, particularly in the cancer setting, is still positive. Some trends can be observed that witness the impact of recent findings in CDK basic biological research and technology advancements on the evolution of the patent literature on CDK inhibition. A patent literature review of small organic molecules as CDK inhibitors comprising the years 2001 - 2004 is presented here, as many of the major pharmaceutical companies have shown a continued effort in the field.",
keywords = "Cancer treatment, Cell cycle, Cyclin-dependent kinase (CDK), Inhibitor",
author = "Paolo Pevarello and Manuela Villa",
year = "2005",
month = "6",
doi = "10.1517/13543776.15.6.675",
language = "English",
volume = "15",
pages = "675--703",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Cyclin-dependent kinase inhibitors

T2 - A survey of the recent patent literature

AU - Pevarello, Paolo

AU - Villa, Manuela

PY - 2005/6

Y1 - 2005/6

N2 - Since the mid-1990s cyclin-dependent kinase (CDK) inhibition has been the subject of an intense drug discovery effort in the pharmaceutical industry and in some academic institutions. Although only few compounds have at present progressed into human clinical trials, the prospect of finding safe agents useful in therapy, particularly in the cancer setting, is still positive. Some trends can be observed that witness the impact of recent findings in CDK basic biological research and technology advancements on the evolution of the patent literature on CDK inhibition. A patent literature review of small organic molecules as CDK inhibitors comprising the years 2001 - 2004 is presented here, as many of the major pharmaceutical companies have shown a continued effort in the field.

AB - Since the mid-1990s cyclin-dependent kinase (CDK) inhibition has been the subject of an intense drug discovery effort in the pharmaceutical industry and in some academic institutions. Although only few compounds have at present progressed into human clinical trials, the prospect of finding safe agents useful in therapy, particularly in the cancer setting, is still positive. Some trends can be observed that witness the impact of recent findings in CDK basic biological research and technology advancements on the evolution of the patent literature on CDK inhibition. A patent literature review of small organic molecules as CDK inhibitors comprising the years 2001 - 2004 is presented here, as many of the major pharmaceutical companies have shown a continued effort in the field.

KW - Cancer treatment

KW - Cell cycle

KW - Cyclin-dependent kinase (CDK)

KW - Inhibitor

UR - http://www.scopus.com/inward/record.url?scp=21244450397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244450397&partnerID=8YFLogxK

U2 - 10.1517/13543776.15.6.675

DO - 10.1517/13543776.15.6.675

M3 - Article

AN - SCOPUS:21244450397

VL - 15

SP - 675

EP - 703

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 6

ER -